Synopsys
SNPS · NasdaqServices-Prepackaged Software · Fiscal year ends Oct 31
Synopsys reported revenue of $7.1B in the fiscal year ended Oct 2025, up 15.1% from the year before. Operating income was $915M, an operating margin of 13.0%, and net income was $1.3B. Operating cash flow of $1.5B less capital expenditure of $169M left free cash flow of $1.3B. Net debt was $10.6B.
Last 5 fiscal years
Revenue and net income
Income statement
| Fiscal year | Oct 2021 | Oct 2022 | Oct 2023 | Oct 2024 | Oct 2025 |
|---|---|---|---|---|---|
| Revenue | $4.2B | $4.6B | $5.3B | $6.1B | $7.1B |
| Cost of revenue | $862M | $898M | $1B | $1.2B | $1.6B |
| Gross profit | $3.3B | $3.7B | $4.3B | $4.9B | $5.4B |
| Research & development | $1.5B | $1.6B | $1.8B | $2.1B | $2.5B |
| Operating income | $735M | $1.1B | $1.3B | $1.4B | $915M |
| Interest expense | $3M | $2M | $1M | $37M | $447M |
| Pre-tax income | $806M | $1.1B | $1.3B | $1.5B | $1.4B |
| Income tax | $49M | $139M | $90M | $100M | $56M |
| Net income | $758M | $985M | $1.2B | $2.3B | $1.3B |
| Diluted EPS | 4.81 | 6.29 | 7.92 | 14.51 | 8.04 |
| Diluted shares | 157M | 156M | 155M | 156M | 166M |
Balance sheet
| Fiscal year | Oct 2021 | Oct 2022 | Oct 2023 | Oct 2024 | Oct 2025 |
|---|---|---|---|---|---|
| Cash & equivalents | $1.4B | $1.4B | $1.4B | $3.9B | $2.9B |
| Receivables | $569M | $796M | $857M | $934M | $1.5B |
| Inventory | $229M | $212M | $326M | $362M | $365M |
| Current assets | $2.8B | $3B | $3.4B | $6.5B | $6B |
| Net PP&E | $472M | $483M | $550M | $563M | $697M |
| Goodwill | $3.6B | $3.1B | $3.3B | $3.4B | $26.9B |
| Total assets | $8.8B | $9.4B | $10.3B | $13.1B | $48.2B |
| Payables | $27M | $38M | $155M | $207M | $165M |
| Deferred revenue | $1.5B | $1.9B | $1.6B | $1.4B | $2.2B |
| Current liabilities | $2.4B | $2.8B | $3B | $2.7B | $3.7B |
| Short-term debt | $75M | $0 | – | $0 | $22M |
| Long-term debt | $25M | $21M | $18M | $16M | $13.5B |
| Total liabilities | $3.5B | $3.9B | $4.1B | $4.1B | $19.9B |
| Shareholders' equity | $5.3B | $5.5B | $6.1B | $9B | $28.3B |
| Backlog (remaining obligations) | $6.9B | $7.1B | $8.1B | $8.1B | $11.4B |
Cash flow
| Fiscal year | Oct 2021 | Oct 2022 | Oct 2023 | Oct 2024 | Oct 2025 |
|---|---|---|---|---|---|
| Operating cash flow | $1.5B | $1.7B | $1.7B | $1.4B | $1.5B |
| Capital expenditure | $94M | $137M | $190M | $140M | $169M |
| Free cash flow | $1.4B | $1.6B | $1.5B | $1.3B | $1.3B |
| Depreciation & amortisation | $204M | $228M | $247M | $295M | $660M |
| Stock-based compensation | $345M | $459M | $563M | $692M | $893M |
| Share buybacks | $753M | $1.1B | $1.2B | $0 | $0 |
Key ratios
| Fiscal year | Oct 2021 | Oct 2022 | Oct 2023 | Oct 2024 | Oct 2025 |
|---|---|---|---|---|---|
| Revenue growth (YoY) | – | 9.8% | 15.2% | 15.2% | 15.1% |
| Operating income growth (YoY) | – | 56.3% | 10.8% | 6.5% | −32.5% |
| EPS growth (YoY) | – | 30.8% | 25.9% | 83.2% | −44.6% |
| Gross margin | 79.5% | 80.5% | 80.6% | 79.7% | 77.0% |
| Operating margin | 17.5% | 24.9% | 23.9% | 22.1% | 13.0% |
| Net margin | 18.0% | 21.3% | 23.1% | 36.9% | 18.9% |
| Return on equityBlank when equity is negative | 14.3% | 17.9% | 20.0% | 25.2% | 4.7% |
| ROCEEBIT ÷ (assets − current liabilities) | 11.6% | 17.3% | 17.3% | 13.0% | 2.1% |
| Free cash flow margin | 33.3% | 34.7% | 28.5% | 20.7% | 19.1% |
| Cash conversion (CFO ÷ net income) | 1.97x | 1.77x | 1.38x | 0.62x | 1.14x |
| Receivable days | 49 | 63 | 59 | 56 | 78 |
| Inventory days | 97 | 86 | 115 | 106 | 82 |
| Payable days | 12 | 15 | 55 | 61 | 37 |
| Interest cover | 218x | 677x | 1081x | 36.8x | 2.05x |
| Debt ÷ equity | 0.02x | 0.00x | 0.00x | 0.00x | 0.48x |
| Net debtDebt − cash & equivalents; excludes investments; negative = net cash | −$1.3B | −$1.4B | −$1.4B | −$3.9B | $10.6B |
| Current ratio | 1.16x | 1.09x | 1.15x | 2.44x | 1.62x |
Recent filings
More in Services-Prepackaged Software
Standardised figures from the company's XBRL filings with the SEC (10-K, 10-Q). Line items follow US GAAP tags, so a company's own statement layout may differ and some lines show “–” where the company does not report that item. Ratios are calculated from these figures. For education only; not investment advice or a recommendation.